Affordable Access

Access to the full text

An Update on Blood-Based Markers of Alzheimer’s Disease Using the SiMoA Platform

Authors
  • Li, Danni1
  • Mielke, Michelle M.2, 2
  • 1 University of Minnesota, Minneapolis, MN, USA , Minneapolis (United States)
  • 2 Mayo Clinic College of Medicine, Rochester, MN, USA , Rochester (United States)
Type
Published Article
Journal
Neurology and Therapy
Publisher
Springer Healthcare
Publication Date
Dec 12, 2019
Volume
8
Issue
Suppl 2
Pages
73–82
Identifiers
DOI: 10.1007/s40120-019-00164-5
Source
Springer Nature
Keywords
License
Yellow

Abstract

The development of blood-based biomarkers of Alzheimer’s disease (AD) pathology as tools for screening the general population, and as the first step in a multistep process to determine which non-demented individuals are at greatest risk of developing AD dementia, is essential. Proteins that are reflective of AD pathology, such as amyloid beta 42 (Aβ42), tau proteins [total tau (T-tau) and phosphorylated tau (P-tau)], and neurofilament light chain (NfL), are detectable in the blood. However, a major challenge in measuring these blood-based proteins is that their concentrations are much lower in plasma or serum than in the cerebrospinal fluid. Single molecule array (SiMoA) is an ultrasensitive technology that can detect proteins in blood at sub-femtomolar concentrations (i.e., 10−16 M). In this review, we focus on the utility of SiMoA assays for the measurement of plasma or serum Aβ42, P-tau, T-tau, and NfL levels and discuss future directions.

Report this publication

Statistics

Seen <100 times